Hopeful about the growing interest in IPF research and investment

Idiopathic pulmonary fibrosis (IPF) is emerging as a “hot spot” for drug development research, according to the nonprofit CheckOrphan, which notes that “investor and industry interest is accelerating.” A May 2026 article on the organization’s website notes recent activity by Avalyn Pharma, which has secured $100 million in research funding, along with recent moves by […] The post Hopeful about the…